Literature DB >> 25969703

Hepatitis C genotypes distribution in intravenous drug users in tehran.

Seyed Moayed Alavian1.   

Abstract

Entities:  

Keywords:  Distribution; Genotype; Hepatitis C

Year:  2015        PMID: 25969703      PMCID: PMC4419385          DOI: 10.5812/jjm.17134

Source DB:  PubMed          Journal:  Jundishapur J Microbiol        ISSN: 2008-3645            Impact factor:   0.747


× No keyword cloud information.
Dear Editor, I read with interest the published article by Ranjbar Kermani et al. (1). Genotyping of hepatitis C virus (HCV) is important, which provides information about strain variation and characteristics of virus during the treatment and the therapy response rate (2). In addition, it is of epidemiologic value because it sheds light on whether prevalent HCV strains are similar to that endemic ones in a certain region, such as those in the Middle East countries (3, 4). The study by Ranjbar Kermani et al. (1) in low sample size but the result in injecting drug users (IDUs) was interesting. This study indicates that the dominant HCV genotypes among patients were 3a and 1a (1). Most of studies in Iran showed that the dominant genotype was1, which is more common than the other genotypes (2, 4, 5). It may be related to their study on IDUs group. Zahedi et al. reported similar data with dominancy of genotype 3 in patients with a history of heroin abuse (6). Hosseini-Moghaddam et al. reported the genotype 3a as a more common genotype in patients underwent hemodialysis in Tehran (7). In comparison with studies made in Yemen, Kuwait, Iraq, and Saudi Arabia, the most common genotype was type 4 (8). However, subtype 1b in Turkey or the western border of Iran and subtype 3a in Pakistan or eastern border of Iran are more prevalent (3). Genotyping was performed using type-specific primers (1) and they did not report any case with mixed genotype. It was related to the limitation of their method, in the other studies from Tehran, mixed HCV genotypes were also found in 2.5% of cases (2). Ranjbar Kermani et al. did not report any data about the relationship between age and distribution of HCV genotypes (1). Jahanbakhsh Sefidi et al. reported that subtype 1a was the most frequent genotype in patients over 40 years of age and subtype 3a was the most frequent ones in patients younger than 40 years old (2). It seems that distribution pattern of HCV genotypes has changed during recent years and today the infection with genotype 3a is increasing among IDUs and general population with HCV infection (9).
  6 in total

1.  Hepatitis C virus (HCV) genotypes and chronic liver disease in Pakistan.

Authors:  H A Shah; W Jafri; I Malik; L Prescott; P Simmonds
Journal:  J Gastroenterol Hepatol       Date:  1997-11       Impact factor: 4.029

2.  Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time.

Authors:  Katayoun Samimi-Rad; Mohsen Nasiri Toosi; Ali Masoudi-Nejad; Ali Najafi; Ramin Rahimnia; Fatemeh Asgari; Alireza Namazi Shabestari; Gholamreza Hassanpour; Seyed-Moayed Alavian; Freshteh Asgari
Journal:  Arch Virol       Date:  2012-06-13       Impact factor: 2.574

3.  Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran--a multicenter study.

Authors:  Seyed Mohammadmehdi Hosseini-Moghaddam; Hossein Keyvani; Hossein Kasiri; Seyed Mohammad Kazemeyni; Abbas Basiri; Nazanin Aghel; Seyed-Moayed Alavian
Journal:  J Med Virol       Date:  2006-05       Impact factor: 2.327

4.  Hepatitis C genotypes in hemophilia patients in iran.

Authors:  F Bokharaei-Salim
Journal:  Iran Red Crescent Med J       Date:  2011-02-01       Impact factor: 0.611

5.  Distribution of hepatitis C virus genotypes in patients infected by different sources and its correlation with clinical and virological parameters: a preliminary study.

Authors:  Ali Kabir; Seyed-Moayed Alavian; Hussein Keyvani
Journal:  Comp Hepatol       Date:  2006-10-02

6.  Distribution of hepatitis C virus genotypes in Iranian chronic infected patients.

Authors:  Fatemeh Jahanbakhsh Sefidi; Hossein Keyvani; Seyed Hamidreza Monavari; Seyed Moayed Alavian; Shahin Fakhim; Farah Bokharaei-Salim
Journal:  Hepat Mon       Date:  2013-01-20       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.